Effects of non-steroidal anti-inflammatory drugs to the gastrointestinal tract;Účinky nesteroidních antiflogistik na gastrointestinální trakt

Casopis Lekaru Ceskych

Volumn 141, Issue 21, 2002, Pages 673-679

  Bureš, Jan ^a   Rejchrt, S ^a   Kopacova M ^a   Siroky M ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Gastrointestinal tract; Non steroidal anti inflammatory drugs; NSAID; Side effects

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CHEMOPROPHYLAXIS; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG ABSORPTION; DRUG METABOLISM; DYSPEPSIA; ESOPHAGITIS; ESOPHAGUS STRICTURE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INHIBITION KINETICS; LIVER INJURY; PRESCRIPTION; RISK ASSESSMENT; STOMACH DISEASE; CHEMICALLY INDUCED DISORDER; GASTROINTESTINAL DISEASE; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GASTROINTESTINAL DISEASES; HUMANS;

EID: 0036445454     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Akre, K., Ekström, A. M., Signorello, L. B. et al.: Aspirin and risk for gastric cancer: A population-based case-control study in Sweden. Brit. J. Cancer, 84, 2001, s. 965-968.
2. Andersson, T., Röhss, K., Bredberg, E., Hassan-Alin, M.: Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment. Pharmacol. Ther., 15, 2001, s. 1563-1569.
3. Bachle, T., Dreher, U., Ruhl, U., Walker, S.: NSAID-induced ulcerative ileocolitis. Med. Klinik, 96, 2001, s. 166-170.
4. Bazzoli, F.: Key points from the revised Maastricht Concensus Report: The impact on general practice. Eur. J. Gastroent. Hepatol., 13, 2001 (Suppl. 2), s. S3-S7.
5. Benoit, R., Grobost, O., Crepeau, T.: Diaphragm-like strictures of the colon induced by diclofenac: a case report. Pres. Med., 30, 2001, s. 1102-1104.
6. Bjarnason, I.: The Effects of Nonsteroidal Anti-inflammatory Drugs on the Small and Large Intestine. AM Mecica Commun., Skokie 1994.
7. Bulíř, K., Pavelka, K.: Výskyt NSA gastropatie u nemocných léčebných dlouhodobě NSA. Čes. Revmatol., 4, 1996, s. 173-178.
8. Bureš, J., Rejehrt, S. et al.: Enteropatie z nesteroidních antiflogistik (s. 197-210). In: Bureš, J., Rejchrt, S. et al.: Vyšetření Tenkého Střeva A Enteroskopický Atlas. Grada, Praha 2001.
9. Doležal, T.: Specifické inhibitory cyclooxygenázy-2 - Coxiby. Remedia, 11, 2001.
10. Dove-Edwin, I., Thomas, H. J. W.: Review article: The prevention of colorectal cancer. Aliment. Pharmacol. Ther., 15, 2001, s. 232-336.
11. DuBois, R. N.: Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and colorectal cancer prevention. Curr. Opin. Gastroenterol., 17, 2001, s. 65-71.
12. Dvořák, Z., Kopáčová, M., Bureš, J.: COX-2 selektivní nesteroidní antirevmatika z pohledu revmatologa a gastroenterologa. Interní Medicína Pro Praxi, 3, 2001, s. 221-226.
13. Gay, R. E., Neidhart, M., Pataky, F. et al.: Dual inhibition of 5-lipoxygenase and cyclooxygenase 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J. Rheumatol., 28, 2001, s. 2060-2065.
14. Goh, K.-L.: Update of indications for treatment of Helicobacter pylori (including Maastricht 2). Curr. Opin. Gastroenterol., 17, 2001 (Suppl. 1), s. S43-S46.
15. Hawkey, C. J., Jackson, L., Harper, S. E. et al.: Review article: The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment. Pharmacol. Ther., 15, 2001, s. 1-9.
16. Hawkey, C. J., Wight, N. J.: NSAIDs and Gastrointestinal complications. Life Science Commun., London 2001.
17. Herings, R. M. C., Klungel, O. H.: An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in the Netherlands. Pharmacoeconomics, 19, 2001, s. 655-665.
18. Jirásek, V., Pulgertová, D., Petrtýl, J. et al.: Omeprazol v léčbě gastropatie z nesteroidních antirevmatik. Prakt. Lék., 81, 2001, s. 146-149.
19. Jonsson, B., Haglund, U.: Economic burden of NSAID-induced gastrophy in Sweden. Scand. J. Gastroenterol., 36, 2001, s. 775-779.
20. Kanji, S., Dumo, P.: The effect of Helicobacter pylori eradication on NSAID-induced gastrointestinal toxicity. Ann. Pharmacother., 35, 2001, s. 249-254.
21. Kopáčová, M., Bureš, J., Široký, M., Rejchrt, S.: Vliv nesteroidních antirevmatik na gastrointestinální trakt. Remedia, 10, 2000, s. 357-361.
22. Kunovská, M., Dítě, P., Lata, J. et al.: Helicobacterpylori negativní leze gastroduodenální u osob léčených NSAID. Vnitř Lék., 46, 2000, s. 384-386.
23. Laine, L.: NSAID-induced Gastrophy: Evaluation of The GI Safety of The Coxibs. 2001 National CME/CE Audioconference Series. http://www.continuing-ed.com.
24. Lazzaroni, M., Bianchi Porro, G.: Review article: Helicobacter pylori and NSAID gastropathy. Aliment. Pharmacol. Ther., 15, 2001 (Suppl. 1), s. 22-27.
25. Morris, A. J.: Nonsteroidal anti-inflammatory drug enteropathy. Gastrointest. Endoscopy Clin. N. Amer., 9, 1999, s. 125-133.
26. Pavelka, K.: Nesteroidní antirevmatika a horní zažvací trakt - II. Část - krváicení. Fyziatr. Věst., 64, 1986, s. 139-146.
27. Pavelka, K.: Gastropatie po aplikaci nesteroidních antirevmatik. Čes. Revmatol., 1, 1993, s. 22-31.
28. Rahme, E., Joseph, L., Kong, S. X. et al.: Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Brit. J. Clin. Pharmacol., 52, 2001, s. 185-192.
29. Rostom, A., Maetzel, A., Tugwell, P., Wells, G.: Ulcer disease and non-steroidal anti-inflammatory drugs: etiology and treatment (s. 91-117). In: Evidence Based Gastroenterology and Hepatology (Eds. J. McDonald, A. Burroughs, B. Feagan), BMJ Books, London 1999.
30. Rybár, I.: Gastropatia Vyvolaná Nesteroidovými Antireumatikami. Osveta, Martin 1997.
31. Sedláčková, M.: Faktory ovlivňujíci průběh infekce Helicobacter pylori-nesteroidní protizánětlivé léky (NSAIDs) (s. 131). In: Sedláčková. M. et al.: Infekce Helicobacter Pylori. Maxdorf Jessenius, Praha 1996.
32. Simon, L. S.: NSAID: Prevention and treatment of gastroduodenal toxicity. UpToDate in Gastroenterology and Hepatology. Wellesley, 9. 1, 2001, http://www.uptodate.com.
33. Simon, L. S.: NSAID: Role in prevention of colorectal cancer. UpToDate in Gastroenterology and Hepatology. Wellesley, 9.1, 2001, http://www.uptodate.com.
34. Stulík, J., Hernychová, L., Porkertová, S. et al.: Proteome study of colorectal carcinogenesis. Electrophoresis, 22, 2001, s. 3019-3025.
35. Tavares, I. A., Borrelli, F., Felsh, N. J.: Inhibition of gastric acid secretion by nimesulide: A possible factor in its gastric tolerability. Clin. Exp. Rheumatol., 19, 2001 (Suppl. 22), s. S13-S15.
36. Voutilainen, M., Mantynen, T., Farkkila, M. et al.: Impact of nonsteroidal anti-infammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease. Scand. J. Gastroenterol., 36, 2001, s. 817-821.
37. Wight, N. J. D., Hawkey, C. J.: Nonsteroidal anti-inflammatory drug-related peptic ulcer disease (s. 102-118). In: Evidence-Based Gastroenterology (Eds. Ervine E. J., Hunt R. H.). BC Decker, Hamilton 2001.
38. Wong Kee Song, L.-M.: NSAID: Adverse effects on the distal small bowel and colon. UpToDate in Gastroenterology and Hepatology. Wellesley, 9.1, 2001, http://www.uptodate.com.
39. Yagi, K., Nakamura, A., Sekine, A., Watanabe, H.: Nonsteroidal anti-inflammatory drug-associated colitis with a histology of collagenous colitis. Endoscopy, 33, 2001, s. 629-632.
40. Yamagiwa, S., Yoshida, Y., Halder, R. C. et al.: Mechanisms involved in enteropathy induced by administration of nonsteroidal antiinflammatory drugs (NSAIDs). Dig. Dis. Sci., 46, 2001, s. 192-199.